Westlake Epoxy Unveils EpoVIVE™ Portfolio at ECS 2025: A New Era of Sustainable Solutions
24.3.2025 21:52:00 CET | Business Wire | Press release
Westlake Corporation (NYSE: WLK) announced today that Westlake Epoxy plans to launch several new products at the European Coatings Show (ECS) 2025, March 25 to 27, 2025, in Germany. Westlake Epoxy will be showcasing at booth # 5-349 its latest innovations designed to enhance robustness, safety, and performance.
At Westlake, we challenge ourselves to do more, to go further in our quest for improved sustainability. As such we strive to develop new technologies that help support customer sustainability initiatives. We are proud to present at ECS our newly introduced EpoVIVE™ portfolio of products that provide sustainability advantages as compared to traditional Westlake formulas in one or more of the following categories:
- Lower Carbon Footprint: Utilize ISCC PLUS mass-balanced bio circular or circular raw materials to reduce carbon emissions.
- Energy Efficiency: Combine renewable energy with energy-efficient practices to reduce the carbon footprint.
- Safer Materials: Use of safer materials that are free from SVHC (substances of very high concern) and CMR (carcinogenic, mutagenic and reprotoxic), improving safe handling.
- Emission Reductions: Achieve lower VOC (volatile organic compounds) waterborne epoxy resin dispersions, contributing to the reduction of VOC emissions during customer applications.
- More Circular Solutions: Support improved circularity with innovative formulations and recycling processes that allow for enhanced ability to reuse, recycle, or repurpose products in the EpoVIVE™ portfolio.
Designed to meet the increasing demand for low-emission, and SVHC-free alternatives that use bio-circular or circular materials, these cutting-edge products offer enhanced durability, corrosion protection, and ease of use while improving our environmental footprint through operational innovations and product offerings with reduced environmental impacts.
The EpoVIVE™ range introduces NEW EPIKOTE™ Resins 901 and 902, providing CMR-free alternatives to conventional C12-C14 diluted resins for high-performance flooring. The portfolio also features the AQUAREOUS™ epoxy systems enabling lower volatile organic compound (VOC), solvent-free coatings for concrete and metal, while SVHC-free AZURES™ products deliver CMR free labelled, high-performance solutions for coatings, civil engineering, and adhesives.
In addition to the EpoVIVE™ portfolio, Westlake Epoxy will introduce the ENABLING Curing Agent EPIKURE™ 6874-WZ-50, which simplifies waterborne formulations and enhances corrosion protection for smooth steel.
"Our commitment to improved sustainability drives us to continuously innovate and deliver solutions that help our customers meet their environmental and performance goals. The launch of the EpoVIVE™ portfolio and related product developments reflect Westlake Epoxy's dedication to reducing the environmental impact of our products while maintaining our high standards of quality and performance," said Karl-Martin Schellerer, Westlake Senior Vice President — Performance and Essential Materials, Europe and Asia.
To learn more about EpoVIVE™ products and Westlake Epoxy’s new innovations for the coatings industry, we invite you to participate in the presentations “New Low labelled Resin Blends for Epoxy Flooring Applications” presented by Patrick Deudon, on Tuesday, March 25th at 14:30 – 14:50, booth # 3-742, Hall 3, and “Novel Waterborne Epoxy Systems: Boosting your Coating Performance”, presented by Dominique Vandenberghe, on Wednesday, March 26th at 13:50 – 14:10, booth # 5-243, Hall 5.
Westlake Epoxy aspires to continuously improve its Environmental, Sustainable and Governance journey. Westlake Epoxy is committed to reducing its carbon footprint through purposefully sourcing more sustainable raw materials, and refining and improving manufacturing processes. Together, we are enhancing your life every day!
About Westlake
Westlake Corporation (NYSE: WLK) is a global manufacturer and supplier of materials and innovative products that enhance life every day. Headquartered in Houston, with operations in Asia, Europe, and North America, we provide the building blocks for vital solutions — from housing and construction, to packaging and healthcare, to automotive and consumer. For more information, visit the company's web site at www.westlake.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250324929717/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Strongest Half-Year in Curatis’s History — Revenue up 51% and Significant Progress on Corticorelin (C-PTBE-01)21.9.2026 07:03:00 CEST | Press release
Curatis Holding AG (SIX:CURN, “Curatis”) reports net sales from goods and services of CHF 7.9m for the first half of 2026, up 51% (H1 2025: CHF 5.2m), with the loss for the period narrowing to CHF -0.4m (H1 2025: CHF -1.2m) and cash and cash equivalents rising to CHF 3.6m (31 December 2025: CHF 1.9m). Curatis also advanced its corticorelin (C-PTBE-01) program on multiple levels, including an exclusive Japan licence with Neupharma and continued manufacturing progress. Business development and finances Net sales from goods increased by 46% to CHF 7.4m (H1 2025: CHF 5.0m) and net sales from services rose to CHF 0.6m (H1 2025: CHF 0.2m). Growth was driven both by products marketed for some time and by products added to the distribution portfolio in 2025 and 2026. The gross contribution from goods and services rose by 32% to CHF 1.8m (H1 2025: CHF 1.3m); the combined cost base grew by only 9% against net sales growth of 51%, as personnel expenses rose 5% to CHF 1.3m (H1 2025: CHF 1.2m) and
Galderma Begins Trading in the Swiss Market Index, Joining Switzerland's Leading Blue Chip Companies21.9.2026 07:00:00 CEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today begins trading as a constituent of the Swiss Market Index (SMI), Switzerland's leading blue chip equity benchmark comprising 20 of the country's largest and most liquid listed companies. Less than three years after its IPO on the SIX Swiss Exchange in March 2024, Galderma has established itself as one of Switzerland's leading listed companies. Its inclusion in the SMI reflects the company's strong growth, disciplined execution and increasing relevance in Swiss and international capital markets as it advances its ambition to become the world's leading dermatology powerhouse. Since its IPO, Galderma has continued to execute its growth-focused integrated dermatology strategy, delivering strong performance across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Net sales increased from 4.410 billion USD in 2024 to 5.207 billion USD in 2025, driven by science-led innovation, portfolio and geogr
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom